病灶内间质注射博来霉素治疗早期颅外动静脉畸形:一项先导研究
这项前瞻性先导研究纳入34例Schobinger I或II期颅外动静脉畸形患者,每月病灶内注射博来霉素(成人单次最大剂量15000 IU,体重不足15 kg儿童按1000 IU/kg)共6个月;末次治疗后3个月评估,27例(84.4%)有反应,其中9例(28.1%)完全缓解,1例(3.1%)发生过敏性休克。
要点
- 早期(Schobinger I或II期)颅外动静脉畸形病灶内注射博来霉素,27/32例(84.4%)治疗有反应。
- 9/32例(28.1%)达完全缓解,4例(12.5%)无反应,1例(3.1%)末次治疗后3个月加重。
- 进一步随访(平均20.7个月)期间31/32例(96.9%)疗效保持稳定。
核心结论
- 病灶内间质注射博来霉素是治疗早期动静脉畸形可行的方法,可获得安全有效的结局。
研究设计与样本
- 前瞻性先导研究,纳入34例按Schobinger分期系统定义为早期(I或II期)的颅外动静脉畸形患者,最终32例完成研究;每例每月注射一次博来霉素、共6个月,成人单次最大剂量15000 IU,体重不足15 kg儿童按1000 IU/kg。
诊断标准与关键数值
- 疗效以末次治疗后3个月血管造影去血管化程度和临床结局评估:27/32例(84.4%,95%CI 71.1–97.7)对博来霉素注射有反应,其中9例(28.1%)完全缓解;4例(12.5%)无反应,1例(3.1%)加重。
临床应用与阅片要点
- 治疗后3个月评估反应,并在进一步随访中评估临床结局;不良反应按美国介入放射学会分类记录,本研究中严重并发症为过敏性休克1例(3.1%,95%CI 0–9.5)。
局限性
- 本文为先导研究(pilot study)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To assess the efficacy and safety of intralesional interstitial bleomycin injection in the treatment of early-stage (Schobinger stage I or II) extracranial arteriovenous malformations (AVMs). Materials and Methods This prospective study involved 34 patients with early-stage AVMs, as defined by the Schobinger staging system. The patients received intralesional interstitial bleomycin injected at a maximum dose of 15 000 IU or 1000 IU per kilogram of body weight for children who weighed less than 15 kg per procedure for a total of 6 months (once every month). Therapeutic outcome was evaluated by the degree of devascularization at angiography and the clinical outcome 3 months after the last treatment. Further follow-up was evaluated based on further clinical outcome. Adverse events were recorded according to the Society of Interventional Radiology classification. Results Of the 34 patients with early-stage AVM, 32 (mean age, 20.5 years; 24 female [75%]) completed the study. The results showed that 27 (84.4%, 95% confidence interval [CI]: 71.1, 97.7) patients were responsive to bleomycin injection, including nine (28.1%) with a complete response. Four (12.5%) patients showed no response, and one (3.1%) patient experienced worsening 3 months after the last treatment. During further follow-up (mean follow-up time, 20.7 months; range, 5-28 months), the outcome remained stable in 31 (96.9%) of the 32 patients. A major complication, anaphylactic shock, was observed in one (3.1%, 95% CI: 0, 9.5) patient. Common minor complications included hyperpigmentation, nausea, pruritus, and bullae. Conclusion Intralesional interstitial bleomycin injection is a feasible approach for early-stage AVMs and yields safe and effective outcomes. © RSNA, 2017.
引用
- Jin Y, Zou Y, Hua C, et al. Treatment of Early-stage Extracranial Arteriovenous Malformations with Intralesional Interstitial Bleomycin Injection: A Pilot Study. Radiology. 2017. PMID: 29237147. doi:10.1148/radiol.2017162076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。